Grufity logoGrufity logo

CCXI

Market Closed

ChemoCentryx Inc

CCXI Stock Price

RSI Chart

Valuation

Market Cap

3.7B

Price/Earnings

-27.87

Price/Sales

99.51

Price/Cashflow

-69.34

Price/Sales

Profitability

Operating Margin

94.59%

Return on Equity

-56.27%

Return on Assets

-31.74%

Fundamentals

Revenue

Revenue (TTM)

37.3M

Revenue Y/Y

-16.27%

Revenue Q/Q

115.48%

Earnings

Earnings (TTM)

-133.1M

Earnings Y/Y

19.28%

Earnings Q/Q

18.02%

Price Action

Last 7 days

0.1%

Last 30 days

0.8%

Last 90 days

121.2%

Trailing 12 Months

54.5%

Financial Health

Current Ratio

4.54

Debt/Equity

0.1

Debt/Cashflow

-2.26

Investor Care

Shares Dilution (1Y)

2.08%

Diluted EPS (TTM)

-2.01

Peers (Alternatives to ChemoCentryx)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
12.84% 43.31%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
1.77% -39.93%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
2.06% 18.94%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
2.84% 55.83%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
8.57% 32.00%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
3.41% 47.17%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
18.65% 56.64%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
0.98% 7.38%
-18.85
63.29
26.15% -23.38%
3.8B
-
46.90% -29.92%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
19.44% -46.75%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
12.93% -47.60%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
20.77% 147.52%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
9.89% -6.61%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
7.77% -61.10%
-1.4
4.57
-43.57% -69.06%
16.0M
-
1.65% -82.57%
-0.46
19.11
-77.61% 5.14%

Financials for ChemoCentryx

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue-14.6%3744505663
  S&GA Expenses9.6%9789796859
  R&D Expenses-8.4%7177838584
Net Income5.4%-133.09-140.65-131.75-121.10-122.86
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-4.8%419440426455468
  Current Assets-1.8%345352269293317
    Cash Equivalents9.4%4441509477
  Inventory89.0%531--
  Net PPE-2.0%3131323334
Liabilities0.6%183182140139137
  Current Liabilities10.6%7669636055
  Long Term Debt0.1%2424242425
    LT Debt, Current3.1%2019191413
    LT Debt, Non Current-12.1%4551012
Shareholder's Equity-8.6%237259286316330
  Retained Earnings-4.8%-687.36-655.70-617.10-576.57-554.26
  Additional Paid-In Capital1.1%926916904892885
Accumulated Depreciation-9----
Shares Outstanding0.3%7171707070
Float-387----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-18.3%-53.50-45.22-75.62-83.96-74.80
  Share Based Compensation1.3%3232313029
Cashflow From Investing22.7%131092120-184.92
Cashflow From Financing16.0%87114

Risks

What is the probability of a big loss on CCXI?

100%


Probability that ChemoCentryx stock will be more than 20% underwater in next one year

73.8%


Probability that ChemoCentryx stock will be more than 30% underwater in next one year.

62.3%


Probability that ChemoCentryx stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CCXI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ChemoCentryx was unfortunately bought at previous high price.

Returns

Cumulative Returns on CCXI

16.8%


10-Year Cumulative Returns

33.5%


7-Year Cumulative Returns

49.2%


5-Year Cumulative Returns

88.7%


3-Year Cumulative Returns

What are the long-term rolling returns for CCXI?

FIve years rolling returns for ChemoCentryx.

Which funds bought or sold CCXI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.08
1,968,000
3,821,000
0.01%
2022-11-21
FourThought Financial, LLC
UNCHANGED
-
-
1,000
-%
2022-11-17
Telemetry Investments, L.L.C.
NEW
-
1,100,000
1,100,000
1.41%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-96,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
REDUCED
-21.53
964,000
2,480,000
0.01%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
381.79
3,067,460
3,406,620
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
36,835,000
36,835,000
0.11%
2022-11-15
STATE STREET CORP
REDUCED
-32.88
40,027,000
140,286,000
0.01%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
174,000
334,000
-%

1–10 of 44

Latest Funds Activity

Are funds buying CCXI calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CCXI

ChemoCentryx News

ETF Daily News

Deutsche Bank AG Increases Stock Holdings in ChemoCentryx, Inc. (NASDAQ:CCXI).30 minutes ago

CCXI Fair Value

Recent SEC filings of ChemoCentryx

View All Filings
Date Filed Form Type Document
Oct 31, 2022
15-12G
15-12G
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading
Oct 24, 2022
4
Insider Trading

Latest Insider Trading transactions for CCXI

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-20
Edwards Thomas A.
GIVEN BACK TO IS
-
-
-143,306
-
2022-10-20
Tyree James L
GIVEN BACK TO IS
-
-
-9,138
-
2022-10-20
Schall Thomas J.
GIVEN BACK TO IS
-
-
-2,393,350
President and CEO
2022-10-20
Parker Geoffrey M.
GIVEN BACK TO IS
-
-
-21,076
-
2022-10-20
Herron Jennifer Lyn
GIVEN BACK TO IS
-
-
-17,237
-
2022-10-20
KANAYA SUSAN M
GIVEN BACK TO IS
-
-
-91,317
See Remarks
2022-10-20
KANAYA SUSAN M
GIVEN BACK TO IS
-
-
-132,717
See Remarks
2022-10-20
Cappel Markus J.
GIVEN BACK TO IS
-
-
-87,658
Chief Bus. Officer & Treasurer
2022-10-20
Parker Geoffrey M.
GIVEN BACK TO IS
-
-
-107,997
-
2022-10-20
Parker Geoffrey M.
GIVEN BACK TO IS
-
-
-5,000
-

1–10 of 50

Thomas J. Schall
180
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

CCXI Income Statement

2022-06-30
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:    
Product Sales Net$ 9,093$ 0$ 14,446$ 0
Product Supply Sales to Related Party86608660
Collaboration and license revenue from related party1,8041,6991,91011,922
Grant revenue01140244
Total revenue11,7631,81317,22212,166
Operating expenses:    
Cost of Sales80301,0080
Research and development14,35520,85331,83144,271
Selling, General and Administrative28,17919,69854,19035,960
Total operating expenses43,33740,55187,02980,231
Loss from operations(31,574)(38,738)(69,807)(68,065)
Other expense:    
Interest income509224731529
Interest expense(586)(695)(1,183)(1,384)
Total other expense, net(77)(471)(452)(855)
Net loss$ (31,651)$ (39,209)$ (70,259)$ (68,920)
Basic and diluted net loss per common share$ (0.44)$ (0.56)$ (0.99)$ (0.99)
Shares used to compute basic and diluted net loss per common share71,23469,78871,03569,698

CCXI Balance Sheet

2022-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 44,396$ 49,978
Short-term investments284,219214,514
Accounts receivable, net4,759411
Accounts receivable from related party18743
Inventory5,474851
Prepaid expenses and other current assets6,1373,380
Total current assets345,172269,177
Property and equipment, net30,85632,269
Long-term investments17,55197,856
Operating lease right-of-use assets24,35924,806
Other assets1,4521,544
Total assets419,390425,652
Current liabilities:  
Accounts payable7,5926,746
Accrued and other current liabilities27,74426,358
Long-term debt, current19,72018,920
Deferred revenue from related party21,02210,993
Total current liabilities76,07863,017
Long-term debt, net4,0054,715
Non-current deferred revenue from related party57,29924,772
Non-current lease liabilities45,24346,830
Other non-current liabilities235198
Total liabilities182,860139,532
Commitments (Note 7)
Stockholders’ equity:  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding00
Common stock, $0.001 par value, 200,000,000 shares authorized; 71,344,838 and 70,357,557 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively7170
Additional paid-in capital926,141903,646
Note receivable(16)(16)
Accumulated other comprehensive loss(2,310)(483)
Accumulated deficit(687,356)(617,097)
Total stockholders’ equity236,530286,120
Total liabilities and stockholders’ equity$ 419,390$ 425,652